



Handwritten signature/initials

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Steven M. Bessette et al.

Atty. Ref.: 4380-151

Serial No. 10/759,177

TC/A.U.: To Be Assigned

Filed: January 20, 2004

Examiner: To Be Assigned

For: CANCER TREATMENT COMPOSITIONS AND METHOD USING
NATURAL PLANT ESSENTIAL OILS

* * * * *

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In compliance with the duty of disclosure requirements under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicant(s) concurrently submit herewith a Form PTO/SB/08a that lists documents containing information that may be considered material to the examination of the above-captioned patent application. A copy of each cited document is also being submitted herewith, if required. No representation is made or intended that (1) more relevant information does not exist, (2) the order of presentation of the information in any way reflects their relative pertinence to the above-captioned patent application, or (3) a search has been made. The Examiner is specifically requested not to rely solely on the information submitted herewith. Applicant(s) respectfully request(s) that the submitted information be expressly considered during the prosecution of this application and that all cited document(s) be made of record therein and appear among the "References Cited" section of any patent to issue therefrom. At least one of the boxes below applies to the present application.

1. ☒ This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement under 37 C.F.R. § 1.97(e) or fee is required.

a. ☐ **Contingent Request to Treat Under 37 C.F.R. § 1.97(c).** In the event a first Office Action has been mailed prior to filing of the present Information Disclosure Statement and the Office Action was mailed more than three months since the filing of the application (for regular applications not including CPAs or RCEs), the Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(c) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p).

b. ☒ **Contingent Request to Treat Under 37 C.F.R. § 1.97(e)(1).** In the event a first Office Action has been mailed prior to the filing of the present Information Disclosure Statement, and the Office Action was mailed more than three months

since the filing of the application (for regular applications not including CPAs or RCEs), the Patent Office is requested to treat the present paper as a submission under 37 C.F.R. § 1.97(e)(1) in that the undersigned hereby states that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

2. ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

c. ☐ I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1). In the event a Notice of Allowance or a Final Rejection has been mailed prior to filing this Information Disclosure Statement, the Patent Office is authorized to treat this as a submission under 37 C.F.R. 1.97(d) and charge the undersigned's Deposit Account No. 14-1140 for the fee required by 37 C.F.R. § 1.17(p).

d. ☐ I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

e. ☐ Attached is our check in the amount of \$____ in payment of the fee under 37 C.F.R. § 1.17(p). If no check is attached, please charge the required fee to the undersigned's Deposit Account No. 14-1140.

3. ☐ This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our check in the amount of \$____ in payment of the fee under 37 C.F.R. § 1.17(i). If no check is attached, please charge the required fee to the undersigned's Deposit Account No. 14-1140.

a. ☐ I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

b. ☐ I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. § 1.56(c) more

than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).

4. ☐ Relevance of some or all of the cited non-English language document(s) is/are discussed in the present specification.

5. ☐ Some or all of the cited document(s) was/were cited in a corresponding foreign application. For the Examiner's information, an English language version of the foreign search report or official action is attached. See MPEP § 609. It is believed that the foreign search report explains the relevance of any non-English language references(s) cited on the attached PTO/SB/08a.

6. ☐ A concise explanation of the relevance of some or all of the non-English language document(s) appears in the Appendix and/or the English-language abstract(s) attached hereto.

7. ☐ Copies of some or all of the documents were cited by or submitted to the Patent Office in parent Application No. _____, filed _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. Thus, copies of these documents are not attached. 37 C.F.R. § 1.98(d).

8. ☐ The Examiner's attention is directed to co-pending and/or related U.S. Patent Application No. _____, filed _____, which is/are directed to related technical subject matter. The identification of the above-listed U.S. Patent Application(s) is not to be construed as a waiver of secrecy as to the application(s), now or upon issuance of the present application as a patent. During the prosecution of the above-captioned patent application, the Examiner is respectfully requested to expressly consider the information contained in any documents submitted to the Patent Office in the above-listed U.S. Patent Application(s).


9. ☐ The publication date indicated on at least one of the listed documents does not indicate a month of publication. However, the year of publication of each listed document is believed to be sufficiently earlier than the effective U.S. filing date and any relied upon foreign priority date. Although a publication date is provided for each document listed on the attached PTO/SB/08a based on the best information presently available to the undersigned, the listed publication date should not be construed as an admission that the information contained in the document was actually published on such listed publication date.

Applicant(s) hereby requests any extension of time deemed necessary for entry of this submission and any submission filed hereafter in this application or any continuing application(s). Applicant(s) makes a Conditional Petition for any relief available to correct any defect in connection with this filing, or any defect remaining in this application after this filing. The Commissioner is authorized to charge any petition fee or any deficiency in fees filed, or asserted to be filed, or which should have been filed herewith (or with any paper filed hereafter) to Deposit Account No. **14-1140** or credit any overpayment of fees to such Deposit Account.

Respectfully submitted,

NIXON & VANDERHYE P.C.


Date: May 5, 2006

By: 
Willem F. Gadiano
Reg. No. 37,136

WFG:ewm
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

(Use several sheets if necessary)



ATTY. DOCKET NO.

4380-151

SERIAL NO.

10/759,177

APPLICANT

Steven M. Bessette et al.

FILING DATE

January 20, 2004

TC/A.U.

To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Al-Harbi, M.M., et al., "Influence of anethole treatment on the tumor induced by Ehrlich ascites carcinoma cells in paw of Swiss albino mice.", <i>Eur. J. Cancer Prev.</i> , 4(4):307-318 (1995) ABSTRACT
	Basu, A., "The potential of protein kinase C as a target for anticancer treatment.", <i>Pharmacol. Ther.</i> , 59(3):257-280 (1993) ABSTRACT
	Caponigro, F., et al., "Protein kinase C: a worthwhile target for anticancer drugs?", <i>Anticancer Drugs</i> , 8(1):26-33 (1997) ABSTRACT
	Chang, C.J., et al., "Oncogene signal transduction inhibitors from medicinal plants.", <i>In Vivo</i> , 10(2):185-190 (1996) ABSTRACT
	Cole K., et al., "Calcium-mediated signal transduction: biology, biochemistry, and therapy.", <i>Cancer Metastasis Rev.</i> , 13(1):31-44 (1994) ABSTRACT
	Crowell, P.L., et al., "Chemoprevention and therapy of cancer by d-limonene.", <i>Crit. Rev. Oncog.</i> , 5(1):1-22 (1994) ABSTRACT
	Crowell, P.L., et al., "Antitumorigenic effects of limonene and perillyl alcohol against pancreatic and breast cancer.", <i>Adv. Exp. Med. Biol.</i> , 401:131-136 (1996) ABSTRACT
	Crowell, P.L., et al., "Structure-activity relationships among monoterpene inhibitors of protein isoprenylation and cell proliferation.", <i>Biochem. Pharmacol.</i> , 47(8):1405-1415 (1994) ABSTRACT
	Gorelick, N.J., "Genotoxicity of trans-anethole in vitro.", <i>Mutat. Res.</i> , 326(2):199-209 (1995) ABSTRACT
	Gould, M.N., "Cancer chemoprevention and therapy by monoterpenes.", <i>Environ. Health Perspect.</i> , 105(Suppl. 4):977-979 (1997) ABSTRACT
	Glazer, R.I., "The protein kinase ABC's of signal transduction as targets for drug development.", <i>Curr. Pharm. Des.</i> , 4(3):277-290 (1998) ABSTRACT
	Grunicke, H. H., et al., "Protein kinase C modulation.", <i>Semin. Cancer Biol.</i> , 3(6):351-360 (1992) ABSTRACT
	He, L. et al., "Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo.", <i>J. Nutr.</i> , 127(5):668-674 (1997) ABSTRACT
	Hohl, R.J., "Monoterpenes as regulators of malignant cell proliferation.", <i>Adv. Exp. Med. Biol.</i> , 401:137-146 (1996) ABSTRACT
	Levitzki, A., "Targeting signal transduction for disease therapy.", <i>Curr. Opin. Cell. Biol.</i> , 8(2):239-244 (1996) ABSTRACT
	Madukar, B. V., et al., "The causes of cancer: implications for prevention and treatment.", <i>Indian J. Pediatr.</i> , 64(2):131-141 (1997) ABSTRACT
	Mihajlovic, V., et al., "Expression of a mutant regulatory subunit of cAMP-dependent protein kinase in the Caco-2 human colonic carcinoma cell line.", <i>Biochem. Cell Biol.</i> , 70(10-11):1039-46 (1992) ABSTRACT
	Newberne, P.M., et al., "Histopathological evaluation of proliferative liver lesions in rats fed trans-anethole in chronic studies.", <i>Food Chem. Toxicol.</i> , 27(1):21-26 (1989) ABSTRACT

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE

CITATION

ATTY. DOCKET NO.

SERIAL NO.

4380-151

10/759,177

APPLICANT

Steven M. Bessette et al.


FILING DATE

TC/A.U.

January 20, 2004

To Be Assigned

(Use several sheets if necessary)



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Palayoor, S. T., et al., "Inhibition of protein kinase C by antieoplastic agents: implications for drug resistance.", <i>Biochem. Biophys. Res. Commun.</i> , 148(2):718-725 (1987) ABSTRACT
	Pawson, T., "Tyrosine kinase signalling pathways.", <i>Princess Takamatsu Symp.</i> , 24:303-322 (1994) ABSTRACT
	Powis, G., "Anticancer drugs acting against signaling pathways.", <i>Curr. Opin. Oncol.</i> , 7(6):554-559 (1995) ABSTRACT
	Powis, G., "Recent advances in the development of anticancer drugs that act against signalling pathways.", <i>Tumori</i> , 80(2):69-87 (1994) ABSTRACT
	Powis, G., et al., "Inhibiting intracellular signalling as a strategy for cancer chemoprevention.", <i>Eur. J. Cancer</i> , 30A(8):1138-1144 (1994) ABSTRACT
	Rompelberg, C.L., et al., "Effect of eugenol on the genotoxicity of established mutagens in the liver.", <i>Food Chem. Toxicol.</i> , 34(1):33-42 (1996) ABSTRACT
	Seedorf, K., "Intracellular signaling by growth factors.", <i>Metabolism</i> , 44(10 Suppl. 4):24-32 (1995) ABSTRACT
	Truhaut, R., et al., "Chronic toxicity/carcinogenicity study of trans-anethole in rats.", <i>Food Chem. Toxicol.</i> , 27(1):11-20 (1989) ABSTRACT
	Uehara, Y., "Protein kinase inhibitor-screening new molecular target therapeutics.", <i>Gan To Kagaku Ryoho</i> , (Article in Japanese), 24(2):136-144 (1997) ENGLISH ABSTRACT
	Umezawa, K., "Isolation and biological activities of signal transduction inhibitors from microorganisms and plants.", <i>Adv. Enzyme Regul.</i> , 35:43-53 (1995) ABSTRACT
	Weinstein, I. B., "Growth factors, oncogenes, and multistage carcinogenesis.", <i>J. Cell Biochem.</i> , 33(3):213-224 (1987) ABSTRACT

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.